Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
McKinsey
Baxter
McKesson
Express Scripts

Last Updated: August 19, 2022

Investigational Drug Information for PF-06650833


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug PF-06650833?

PF-06650833 is an investigational drug.

There have been 12 clinical trials for PF-06650833. The most recent clinical trial was a Phase 2 trial, which was initiated on January 6th 2021.

The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and COVID-19. The leading clinical trial sponsors are Pfizer, Yale University, and Giovanni Franchin, M.D, Ph.D.

There are five US patents protecting this investigational drug and seventy-four international patents.

Recent Clinical Trials for PF-06650833
TitleSponsorPhase
A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)PfizerPhase 1
IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.PfizerPhase 2
IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.Giovanni Franchin, M.D, Ph.DPhase 2

See all PF-06650833 clinical trials

Clinical Trial Summary for PF-06650833

Top disease conditions for PF-06650833
Top clinical trial sponsors for PF-06650833

See all PF-06650833 clinical trials

US Patents for PF-06650833

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06650833 See Plans and Pricing Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY) See Plans and Pricing
PF-06650833 See Plans and Pricing Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY) See Plans and Pricing
PF-06650833 See Plans and Pricing IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (Cambridge, MA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
McKinsey
Baxter
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.